Lifeward Ltd. 8K

Lifeward furnished a September 2026 investor presentation describing its current rehabilitation technology portfolio, growth pipeline, reimbursement strategy, and funding partnership with Oramed Pharmaceuticals.

Lifeward Holdings Corp. furnished an investor presentation dated September 2026 outlining its restorative healthcare platform strategy, including its existing ReWalk exoskeleton and AlterG anti-gravity rehabilitation businesses, a pipeline of robotic and AI-enabled rehab devices with anticipated FDA clearance and commercial launch dates through 2030+, its transition toward a capital-efficient channel-partner distribution model, established reimbursement infrastructure (including Medicare Advantage and VA coverage and a defined HCPCS code and fee schedule for ReWalk), and the terms and strategic rationale of its funding and development partnership with Oramed Pharmaceuticals related to the Protein Oral Delivery (POD) platform and oral insulin candidate ORMD-0801.

Filing Facts

CIK

1607962

Ticker

-

Form

8K

Source Type

sec

Accession

0001178913-26-004440

Alert Tier

5